Prophylactic therapy for cytomegalovirus in liver transplant recipients: a single center experience with oral ganciclovir versus valganciclovir

Trial Profile

Prophylactic therapy for cytomegalovirus in liver transplant recipients: a single center experience with oral ganciclovir versus valganciclovir

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Ganciclovir (Primary) ; Valganciclovir (Primary)
  • Indications Cytomegalic inclusion disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top